Profiling the safety and tolerability of bisphosphonates

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 73-78

  Body, Jean Jacques ^a   Diel, Ingo ^b   Bell, Richard ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b Inst for Gynaecological Oncology   (Germany)

^c Andrew Love Cancer Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANEMIA; ARTHROPATHY; ASTHENIA; BACKACHE; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM BLEEDING; DYSPEPSIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTRITIS; GASTROENTERITIS; HEADACHE; HUMAN; HYPOCALCEMIA; INJECTION SITE; KIDNEY FUNCTION; KIDNEY INJURY; LONG TERM CARE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MASTALGIA; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY;

EID: 5644290689     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.030     Document Type: Conference Paper

References (31)

1. I.J. Diel, E.F. Solomayer, G. Bastert Treatment of metastatic bone disease in breast cancer bisphosphonates Clin Breast Cancer 1 2000 43 51
2. B.E. Hillner, J.N. Ingle, J.R. Berenson American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer J Clin Oncol 18 2000 1378 1391
3. B. Kristensen, B. Ejlertsen, M. Groenvold Oral clodronate in breast cancer patients with bone metastases a randomized study J Intern Med 246 1999 67 74
4. J.J. Body Dosing regimens and main adverse events of biphosphonates Semin Oncol 28 suppl 11 2001 49 53
5. T. Powles, S. Paterson, J.A. Kanis Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 2002 3219 3224
6. S. Atula, T. Powles, A. Paterson Extended safety profile of oral clodronate after long-term use in primary breast cancer patients Drug Safety 26 2003 661 671
7. Van Poznak CH The use of bisphosphonates in patients with breast cancer. Cancer Control 9 2002 480 489
8. R. Coleman Efficacy of zoledronic acid and pamidronate in breast cancer patients a comparative analysis of randomized phase III trials Am J Clin Oncol (CCT) 25 suppl 1 2002 S25 S31
9. G.S. Markowitz, P.L. Fine, J.I. Stack Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 2003 281 289
10. L.S. Rosen, D. Gordon, S. Tchekmedyian The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors a phase III, double-blind, randomized trial J Clin Oncol 21 2003 3150 3157
11. B.E. Hillner, J.N. Ingle, R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042 4057
12. J.J. Body, I.J. Diel, M.R. Lichinitser Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
13. D. Tripathy, M. Lichinitzer, A. Lazarev Oral ibandronate for the treatment of metastatic bone disease in breast cancer efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann Oncol 15 2004 743 750
14. J.J. Body, I.J. Diel, M. Lichinitzer Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
15. S. Rivkin, J.J. Body, I. Diel Long-term safety of intravenous (i.v.) ibandronate given as bolus injection or infusion for up to 4 years in metastatic bone disease results of an open-label study 2003 Abstract presented at the IVth International Conference on Cancer-Induced Bone Diseases, San Antonio, TX, December 7-9
16. S.-A. McLachlan, R. Murray, D. Tripathy Long-term safety of oral ibandronate for up to 4 years in patients with skeletal metastases from breast cancer 2003 Abstract presented at IVth International Conference on Cancer-Induced Bone Diseases, San Antonio, TX, December 7-9
17. J.J. Body, M. Lichinitser, N. Andreeva Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease results of an open-label study [abstract 735] Proc Am Soc Clin Oncol 23 2004 60
18. A. Heidenreich, C. Ohlmann, P. Olbert High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer [abstract 897] Eur J Cancer 1 suppl 5 2003 S270
19. I. Mancini, J.C. Dumon, J.J. Body Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease a pilot study J Clin Oncol 22 2004 3587 3592
20. L.S. Rosen, D. Gordon, M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma a phase III, double-blind, comparative trial Cancer 7 2001 377 387
21. K.B. Johnson, P. Gable, E.M. Kaime Significant deterioration in renal function with the new bisphosphonate, zoledronic acid [abstract 2968] Proc Am Soc Clin Oncol 22 2003 738
22. D.D. Kloth, R.S. McDermott, A. Rogatko Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer is constant monitoring necessary? [abstract 3036] Proc Am Soc Clin Oncol 22 2003 755
23. S.H. Stein, R. Davidson, A. Tweed Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer - University of Pennsylvania [abstract 2997] Proc Am Soc Clin Oncol 22 2003 745
24. D. Banerjee, A. Asif, L. Striker Short-term, high-dose pamidronate-induced acute tubular necrosis the postulated mechanisms of bisphosphonate nephrotoxicity Am J Kidney Dis 41 2003 E18
25. J.T. Chang, L. Green, J. Beitz Renal failure with the use of zoledronic acid N Engl J Med 349 2003 1179 1676
26. T. Pfister, E. Atzpodien, F. Bauss The renal effects of minimally nephrotoxic doses of ibandronate and zoledronic following single and intermittent intravenous administration in rats Toxicology 191 2003 159 167
27. R. Bell, I.J. Diel, J.J. Body Renal safety of ibandronate in patients with bone metastases from breast cancer phase III trial results Eur J Cancer Suppl 2 2004 132
28. L.S. Rosen, D. Gordon, M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
29. G. Neugebauer, W. Koehler, L. Akinkunmi Influence of peak ibandronic acid concentrations after 6 mg i. v. administration with shortened infusion time (15 and 30 minutes) on renal safety in man [abstract 486] Proc Am Soc Clin Oncol 20 2001 122A
30. J. Barrett, E. Worth, F. Bauss Ibandronate a clinical pharmacological and pharmacokinetic update J Clin Pharmacol 44 2004 951 965
31. N.V. Lyubimova, N.E. Kushlinsky, M.R. Lichinitser Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease Clin Drug Invest 23 2003 707 716